

## Update on the work on the Insurance Distribution Directive (IDD)

**David Cowan** Project Manager on the Insurance Distribution Directive (IDD), EIOPA

Presentation to Insurance & Reinsurance Stakeholder Group, 26 April 2016

## Summary / agenda



#### <u>Issue</u>

 Progress report on EIOPA's work on the Insurance Distribution Directive (IDD)

#### Actions asked from IRSG

- No specific action required at this stage as EIOPA work is still "in progress"
- Ad hoc oral/written feedback on any issues raised in the presentation, much appreciated however

#### Follow up

- Further update at next IRSG meeting on 9 June 2016
- Potential for sharing elements of draft technical advice with IRSG

## IDD - Essentials



- Entry into force 23 February 2016
- Transposition deadline 24 months (i.e. 23 February 2018)
- Key <u>imminent</u> deliverables for EIOPA:
  - o **Technical advice** on <u>four</u> Delegated acts:
    - Product Oversight & Governance (Article 25) ALL products
    - Conflicts of Interest (Articles 27 & 28) only IBIPs
    - **Inducements** (Article 29) <u>only</u> IBIPs
    - Suitability, Appropriateness and Reporting to customers (Article 30) only IBIPs
  - o Formal Call for Advice from COM received on 24 February 2016
  - o Submit technical advice to COM by 1 February 2017

# IDD – Essentials (cont.)



- **Implementing Technical Standards** on the "Product Information Document (PID)" for non-life products (Article 20(9))
  - o Regarding "standardised presentation format"
  - o Consumer testing required
  - o Submit 12 months after entry into force i.e. **23 February 2017**
- **Guidelines** on the assessment of IBIPs not fit for executiononly business (Article 30(7)):
  - o See MiFID II Guidelines on complex debt instruments and structured products
  - o Issue Guidelines 18 months after entry into force i.e. **23 August 2017**



# **Delegated Acts**

# Key overarching issues



#### • Consistency with MiFID II?

- o What if the wording in IDD is fundamentally different?
- o Regulatory scrutiny of MiFID II delegated acts ongoing "moving target"

#### • Cumulative effect of Chapters V and VI

 Level 1 - General conduct of business requirements & IBIPs requirements apply <u>cumulatively</u> – also at Level 2?

#### • Minimum harmonisation L1 vs. Delegated Acts

- o Interplay between minimum harmonisation & delegated act does it mean delegated acts must be in the form of Directives?
- **Proportionality** diversity of products/distribution channels

# **Product Oversight & Governance**



#### Key Issues to consider:

- **o** Responsibilities of manufacturer & distributor
- Sharing of information between manufacturer & distributor consequences of lack of information?
- Defining the target market level of granularity IBIPs vs. Non-IBIPs
- Proportionality

# **Conflicts of Interest & Inducements**



#### Key Issues to consider:

- Technical advice on "IMD 1.5" as a baseline
- Interaction between conflicts of interest & inducement provisions
- o "No detrimental impact" vs. "Quality enhancement"?
- o COM wants methodology for "no detrimental impact" -Blacklists/Whitelists?

## Suitability, Appropriateness & Reporting to customers



Key Issues to consider:

- o Very new for some Member States "MiFID-isation"
- Interaction with overarching "demands and needs" requirement in General Chapter
- Which IBIPs could classify as "other non-complex"?
- **Professional customers in life insurance?**



# IPID

## What is IPID trying to fix?



• Consumer **level of engagement** with disclosures

• Difficulty in **comparison** between products

• Expectations v actual cover e.g. policy exclusions

• Too much focus on price

## **Consumer testing**



- Procurement contract signed with <u>London Economics</u> for design work and consumer testing
- Two rounds of consumer testing in <u>four</u> countries
- 1st round: <u>qualitative</u> testing of 5 designs in focus groups
- 2nd round : <u>quantitative</u> testing of 3 designs using online questionnaires


#### Timetable for consumer testing and BoS (end dates)

- Consumer testing phase 1 6 May
  Consumer testing phase 2 24 June
  Report finalised 19 August
  Consultation paper BoS (written procedure) end July
  Consultation (12 weeks) 31 Oct
- ITS BoS January 2017
- Deliver to Commission

 $\mathbf{P}$ 

23 Feb 2017

## **IDD timeline (2016-2017)**





# **Opportunities for Stakeholder Input**

## **Stakeholder Input**



• Online survey for technical input – end of January 2016

• Regular IRSG updates

• 3 month public consultation from end of June 2016

• 23 September 2016 – IDD Public Hearing



## **Questions?**

David Cowan David.Cowan@eiopa.europa.eu phone: +49 69 95 1119 26